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Abstract 
The concept that viral infection contributes to the development of autoimmune 
disease is supported by a wide range of clinical and experimental observations. TRIM 
family members, and particular the SPRY/PRY sub-class, are known for their 
involvement in anti-viral immunity – as either viral restriction factors or as regulators 
of pathways downstream of anti-viral RNA and DNA sensors. Interestingly, new data 
suggests that TRIMs also regulate the inflammasome. Therefore, whether as 
autoantigens or as regulators of anti-viral responses, evidence is emerging that 
TRIMs contribute to the development and pathology of autoimmune and 
autoinflammatory disease, making them novel targets for therapeutic manipulation.  
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The mammalian immune system has evolved to contain a wide range of 
membrane-bound and cytosolic pathogen recognition receptors (PRRs), which 
recognise and respond to specific molecular patterns from a variety of microbes. The 
intracellular signalling pathways that are activated downstream of PRRs drive the 
production of proinflammatory cytokines and type I interferons (IFNs), which initiate 
a rapid potent immune response and activate downstream effector and memory 
cells. Links exist between viral infections, induction of the innate immune response 
and the development of autoimmunity. For example, infection with viruses is often 
accompanied by the appearance of autoantibodies against self antigens. Epstein Barr 
Virus (EBV) infection for instance results in the generation of autoantibodies against 
autoantigens associated with the autoimmune disease systemic lupus 
erythrematosus (SLE), such as TRIM21/Ro52, Ro60 and La [1, 2]. These arise 
primarily as a result of molecular mimicry in the case of Ro60 and La, but also as a 
result of exposure of the autoantigens to the immune system following cellular 
insult. Ro52/TRIM21 for example, a cytosolic protein under normal conditions, is 
exposed at the cell membrane following ultraviolet irradiation of keratinocytes [3, 4]. 
In addition, the pathogenesis of many autoimmune conditions is driven by the 
overproduction of cytokines associated with viral infection, such as tumour necrosis 
factor (TNF)-α and type I interferons (IFN). SLE patients characteristically display 
elevated type I IFN (IFN-α and IFN-β) levels in their serum during flare periods of this 
disease (reviewed in [5, 6]). The molecular mechanism behind the overproduction of 
type I IFN is now well recognised to be as a result of recognition of self RNA and DNA 
complexes by pathogen recognition receptors (PRRs) such as the Toll-like receptor 
(TLR)- and -9, in addition to intracellular nucleic acid sensing systems.  
 
In recent years, members of the tripartite motif (TRIM) family, perhaps best known 
as anti-viral proteins, have emerged as important regulators of PRR signalling 
pathways[7, 8]. Several TRIM proteins, such as TRIM5α[9], 22[10] and 28[11], have 
direct anti-viral properties and together can restrict several stages of the viral 
replication cycle[7, 8, 12]. Complementing this, TRIMs have both positive and 
negative regulatory functions in PRR pathways[8]. Many TRIMS are both IFN-
inducible and regulate IFN production, which has led to the hypothesis that a subset 
of TRIMs, and in particular TRIM21[13], are involved in a negative regulatory 
feedback loop for IFN-mediated immunity[14]. The range of immune-related 
properties ascribed to the TRIM family continues to increase and recent research has 
implicated TRIM16 (also called estrogen-responsive B box protein)[15], TRIM20 (also 
called pyrin)[16] and TRIM30[17] in the regulation of interleukin (IL)-1β production 
via the inflammasome, which has a vital role in autoinflammatory conditions. Since 
IL-1β is well known to be involved in a multitude of inflammatory and autoimmune 
processes[18], an improved understanding of how TRIMs regulate inflammasome 
pathways might lead to the identification of therapeutic targets or the development 
of novel therapies for autoinflammatory disorders. 
 
The unfolding story of the TRIMs is quickly establishing this family of proteins as 
crucial anti-viral and regulatory signalling molecules in PRR, inflammasome and 
autoimmune pathways. In this Review, we provide an update on the contribution of 
TRIMs to antiviral protection and innate immune regulation and discuss the 
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emerging role of specific TRIMs in the molecular mechanisms and pathways 
associated with inflammation and autoimmunity.  
 
TRIMs – Structure, Function and Expression 
 
Structure 
Since the first TRIM was cloned from Xenopus laevis mRNA in 1991[19], TRIM genes 
have been found in a wide range of species from fish[20] to pigs[21] to humans[22]. 
In total, genetic information is available for 68 human TRIMs (and several TRIM-like 
genes)[22], the majority of which have the characteristic really interesting new gene 
(RING)-finger, B-box and coiled coil (RBCC) domains (Figure 1 and Supplementary 
Figure 1). Most TRIM proteins share high sequence similarity in the RBCC domains. 
Indeed, the main variability is found in the C-terminal domains, a region that appears 
to dictate the specific function of each individual protein (Box 1). Although there 
seems to be little correlation between genomic location and structure, six of the 
eight TRIM genes that cluster at chromosome 6p21-23 (TRIM10, 15, 26, 27, 38 and 
39) and all of the TRIMs at 11p14-15 (TRIM5, 6, 21, 22, 34 and 68) contain a SPRY 
domain (Figure 1b), which is increasingly being linked to anti-viral and innate 
immune responses. It has been proposed that the human TRIM family is split into 
two distinct groups (Group 1 and 2) that evolve at different rates and are subject to 
different selective pressures[22]. Group 1 members are found in both vertebrate and 
invertebrate species and contain a range of C-terminal domains. By contrast, 
members of Group 2, which include the majority of the clustered genes at 6p21-23 
and 11p14-15, are not found in invertebrates and contain a C-terminal SPRY domain. 
Overall, the evidence suggests that Group 2 TRIMs are the largest sub-group, 
(accounting for 40/71 family members (as shown in Supplementary Figure 1)) and 
may have a more recent origin, and thus have evolved more rapidly, than members 
of Group 1[22]. This accelerated divergence and positive selection of Group 2 TRIMs 
might, in part, be attributable to the critical role that many PRY/SPRY-containing 
TRIMs have in the immune response against rapidly mutating viruses as will be 
discussed below.  
 
 
 
E3 ligase activity 
 
The RING-finger domain of TRIMs and other protiens is long established as 
conferring the ability to act as an E3 ubiquitin ligase[23]. Following the contribution 
of E1 and E2 enzymes, this enables the RING-finger-containing protein to assist in the 
transfer of single or multiple ubiquitin moeities from the E2 ligase onto a target 
protein. As the majority of TRIMs possess a RING-finger domain, it is not surprising 
that many family members have been shown to self-ubiquitinate and/or to promote 
the ubiquitination of target proteins[24-26] including important proinflammatory 
and IFN signalling molecules, such as inhibitor of NFκB kinases (IKKs)[27] and IFN 
regulatory factors (IRFs)[28]. Ubiquitinated proteins are subsequently degraded, 
activated or trafficked to other locations in the cell – the particular outcome is 
thought to be mostly dependent on the specific lysine on the ubiquitin molecule 
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employed to facilitate poly-ubiquitination[29]. TRIMs are also known to contribute 
to the post-translational modification of target proteins mediated by SUMO[30] and 
ISG15[31]. 
 
 
Expression 
 
TRIMs are expressed in the cytosol and nucleus of most cell types, indicative of a 
family of proteins with a wide array of functions. The expression of TRIM19/PML is 
particularly distinct in that it forms the mass bulk of nuclear bodies, and has several 
physiological roles including the regulation of transcription[32] and interferon-
mediated innate immunity[33]. Many other TRIMs seem to localise to unidentified 
cellular compartments; an observation confirmed by studying the localization 
patterns of mutated TRIMs[34]. As many TRIMs have direct and indirect anti-viral 
properties, a reasonable hypothesis was that TRIMs would be induced following 
activation of the classic anti-viral type I IFN pathway. Accordingly, several studies 
have shown that various TRIMs are type I IFN-inducible (Table 1)[35-38].  
On the basis of mRNA expression data of murine TRIMs in various immune 
cell subsets, Rajsbaum et al. noted that many TRIMs, including TRIM19, 20 and 21, 
were highly expressed in macrophages and DCs under conditions which are known 
to induce type I IFN (i.e. influenza virus infection or TLR-9 stimulation), suggesting 
that these mRNAs are IFN-inducible. Indeed, the observed induction of mRNA 
expression was abrogated in IFN-α/-βR
-/-
 mice [37], confirming that these TRIMs are 
induced via a type I IFN-dependent mechanism.  
In a separate study, human TRIM mRNAs were analysed for IFN-inducibility in 
several immune cell subsets [36]. Overall, 16 TRIM mRNAs  were induced following 
type I IFN stimulation of primary monocyte-derived macrophages (MDM), while all 
but two were also upregulated in stimulated peripheral blood lymphocytes (PBL) 
(Table 1). Type II IFN stimulation induced the expression of only 7 TRIMs in each cell 
type. Both type I and II IFNs also downregulated a number of TRIMs in MDMs such as 
TRIM16, although only TRIM16L showed reduced mRNA expression in PBLs. In 
addition, FcγR signalling induced the mRNA expression of TRIM9 and 54 in MDM and 
downregulated 8 other TRIM mRNAs. Multiple TRIM mRNAs have also been shown 
to be either upregulated or downregulated following stimulation of human 
macrophages with LPS and IFN-γ (Table 1). Overall, the cell-type specificity of TRIM 
expression, along with the selective inducibility following type I and II IFN signalling, 
allows the TRIM family to provide a multi-layered anti-viral response and 
simultaneously perform critical immunoregulatory functions. 
 
 
TRIMs, the anti-viral response and potential links with autoimmune 
and autoinflammatory disease 
 
The importance of TRIMs, particularly PRY/SPRY domain containing family members, 
in regulating the anti-viral response is well established and is underlined by the fact 
that many are targets for viral degradation [39, 40], and has been reviewed 
extensively [7, 8]. Interestingly, a number of pathogens express pyrin-only domains 
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which have been shown to inhibit IL1/IL18 production presumably by disrupting the 
inflammasome (reviewed in [41]). Conceivably, a similar strategy could be used by 
viruses to encode TRIM family proteins in order to limit the IFN or inflammatory 
response.  
With respect to TRIMs in autoimmunity, the role for several members (TRIM21 and 
TRIM68 in particular) as autoantigens in autoimmune dieases such as SLE and 
Sjogren’s syndrome (SS) is well established. However, given the link between anti-
viral responses and autoimmunity, newly emerging data on the role of this family as 
antiviral restriction factors and regulators of cytokine production downstream of 
viral recognition systems, suggests a role for TRIMs in protecting against 
autoimmune disease. In addition the growing realisation that certain TRIMs function 
to regulate the inflammasome, suggests a potential mechanism whereby defects in 
these proteins can contribute to autoinflammatory conditions associated with 
overproduction of IL-1β. These various roles of TRIMs will now be explored, 
specifically in the context of implications for autoimmune and autoinflammatory 
conditions. 
 
 
TRIMs as autoantigens 
 
The protective antibody response accompanying viral infection is often accompanied 
by the appearance of autoantibodies against self proteins, with obvious pathogenic 
potential. Several mechanisms exist to explain how these autoantibodies arise. In 
general viral-induced production of autoantibodies against self proteins 
accompanies their exposure to the immune system as a result of cell death, changes 
in intracellular localisation or as a result of post-translational studies.  
For example, recognition of TRIM21/Ro52, an autoantigen associated with 
SLE, is associated with altered membrane localisation and enhanced protein 
expression as a result of viral infection or cell injury [3, 4, 42].  TRIM68, an 
autoantigen in Sjogren’s Syndrome and SLE, is also similarly exposed [43]. Several 
studies have reported the link between viral infection and the development of auto-
reactive antibodies and a number of these have demonstrated the production of 
antibodies specific to TRIM family members [2]. In addition to EBV infection giving 
rise to autoantibodies against Ro52/TRIM21, infection of mice with vaccinia virus or 
the non-cytopathic lymphocytic choriomeningitis virus revealed TRIM2-specific 
antibodies being induced. Whilst suggestive that TRIM2 expression or location within 
the cell maybe altered following viral infection, as yet no linkage for the involvement 
of TRIM2 in autoimmune disease exists. Recently autoantibodies against TRIM33 
(TIF1 γ) and the intracellular apathogen recognition receptor (PRR) MDA-5 have been 
identified in patients suffering from the autoimmune connective tissue disease [44]. 
TRIM33 is best known for its role as a transcriptional repressor, although recently a 
role for it in regulating TGF-β signalling has been described [45], indicating it may 
have an as yet undiscovered role in immune regulation. Whilst the pathophysiology 
of autoantibodies is clearly established, it is unclear as yet as to whether 
autoantibodies against TRIM family members have any specific role to play other 
than as markers of disease. The possibility exists that autoantibodies against specific 
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targets may function to inappropriately sequester their targets, thus affecting their 
function. In the case of autoantibodies against Ro52/TRIM21, this may be 
particularly relevant, particularly in light of its role as a negative regulator of type I 
IFN production as discussed below.  
 
 
TRIMs as viral restriction factors and potential link with autoimmunity 
– an update 
With respect to a role for TRIMs as viral restriction factors there has been an 
explosion of information in recent years [8, 46, 47]. In particular, a study by Uchil et 
al [47] in which they screened various human and mouse TRIMs, demonstrated that 
TRIMs act nearly every stage in viral replication (summarised in table 2).  This section 
aims to provide an update on emerging TRIMs in this area and potential links with 
autoimmunity. 
 
TRIM5α and TRIM22: Perhaps the best studied of all the TRIMs in this respect, 
TRIM5α was discovered in 2004 as a retroviral restriction factor that determined the 
species restriction of HIV-1 [48] [49] [50]. It has multiple roles in inhibiting retroviral 
lifecycle, including recognition of the viral capsid by its SPRY/PRY domain [51] and 
more recently it has been shown to have direct effects on signal transduction 
pathways that may restrict retroviral replication [52], such as targeting NFκB and 
inflammasome activity as discussed below. Its close homologue, TRIM22, functions 
to inhibit HIV budding from infected cells [53]. Recent evidence also demonstrates 
an inverse correlation between viral load and expression of TRIM22, reinforcing its 
role as a potent restriction factor against HIV in vivo [54]. 
A genetic study investigating the role of human endogenous retroviruses (HERV) in 
multiple sclerosis (MS), demonstrated an inverse correlation between SNPs in 
TRIM5α and MS. This suggests that certain SNPs may be protective against the 
development of MS, whether through restricting the effects of endogenous 
retroviral transmission or via its newly uncovered role as a regulator of NFκB/NLRP3 
activation (see below). Indeed SNPs in TRIM5α have already been demonstrated to 
be protective against HIV infection, revealing a protective role for this TRIM protein 
for human health. 
 
TRIM28: Endogeneous retroviruses (ERV) are retroviral elements that comprise 
about 10% of mammalian DNA. They are transcriptionally silenced during early 
embryogenesis via histone and DNA methylation in order to protect genome 
integrity. TRIM28 has been identified as a key protein that supresses ERV expression 
via recruiting a complex series of proteins required to methylate histones [11, 55]. 
The recently emerging roles for  human ERVs (HERV) in autoimmunity (ranging from 
direct effect of HERV genes on immune regulated pathways or HERV proteins acting 
as superantigens in the induction of autoantibody responses) and cancer suggest 
that TRIM28 (and potentially other TRIM family members) maybe important in 
regulating these diseases [56, 57]  
 
Therefore in addition to the role of TRIMs as viral restriction factors, it is now 
emerging that TRIMs play a more fundamental role in regulating anti-viral immune 
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defences at various different levels as discussed below and combined these two 
important aspects of TRIM biology may explain the emerging data suggesting an 
involvement for TRIMs in autoimmune and autoinflammatory disorders.  
 
 
TRIMS and pathogen recognition pathways 
 
TRIM proteins act as either positive or negative regulators on the pathways 
downstream of pathogen recognition receptors, the majority requiring their E3 ligase 
activity for activation (via K63-linked polyubiquitination) or degradation (via K48-
linked polyubiquitination) of key signalling molecules. Anti-viral sensors principally 
detect viral nucleic acid, and under pathogenic circumstances can detect RNA and 
DNA released from damaged host cells. They include the Toll-like receptors (TLRs), 
the cytoplasmic RIG-like helicase receptors (RLRs), the inflammasome whose 
assembly is controlled by a subset of the NOD-like receptors (NLRs) and the newly 
described HIN family of proteins that function as intracellular double stranded (ds) 
DNA receptors. IFN-α and -β (via activation of the transcription factors IRF3 and IRF7) 
and proinflammatory cytokines (via NFκB activation) are rapidly induced as a result 
of recruitment of specific adaptor and effector proteins as illustrated in Figure 2.  
 
NFκB is the prototypical proinflammatory transcription factor, regulating the 
expression of proinflammtory cytokines (TNF, IL1, IL12 etc) and the upregulation of 
adhesion molecules and activation markers in order to promote the inflammatory 
response. Activation requires phosphorylation and degradation of the inhibitory 
protein IκB by upstream kinases IKKα and β, prior to release and nuclear 
translocation of NFκB. For both the TLR and RLR pathways the common convergence 
point in the activation of NFκB is the E3 ligase TRAF6. Autoubiquitination of TRAF6 
results in recruitment of the adaptor proteins TAB2 and TAB3 and the kinase TAK1, 
resulting in activation of IKKs ([58] and reviewed in [59, 60]). Highlighting the 
importance of the TAB1/TAK1 in regulating NFκB activation, TRIM5α and its murine 
orthologue TRIM30 have been shown to interact with, ubiquitinate and degrade 
TAB2 and TAB3, resulting in disruption of the TRAF6/TAK1/TAB complex and 
inactivation of NFκB dependent pathways ([61, 62]). 
 
The role of type I interferons in driving autoimmune disease is well established, with 
elevated IFN-α/-β observed in patients suffering from SLE, Sjogren’s syndrome, 
dermatomyositis and psoriasis and is strongly correlated with both inflammation and 
disease-associated tissue damage. As IFN-α and -β are produced in response to viral 
detection, either via their recognition by TLRs, RLRs or intracellular DNA sensors, it is 
components of these pathways that are generally targeted in order to limit or fine 
tune cytokine production. Activation of IRF3 or IRF7 downstream of TLR3, RLRs and 
cytosolic DNA receptors requires the activation of non-canonical IKK family 
members, TANK-binding kinase 1 (TBK1) and IKKε in a process involving TRAF3 and 
recruitment of signalling complexes to mitochondrial compartments. Activation of 
IRF7 downstream of TLR7 and TLR9 involves recruitment of IKKα to TRAF6-containing 
complexes at the endosome, in a process that requires ubiquitination in addition to 
phosphorylation of IRF7 [63]. As key regulators of anti-viral signalling, TRIM family 
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members are increasingly recognised for their involvement in regulating these 
pathways via effects thus far identified at the level of the receptors themselves, the 
IKK complexes and as direct regulators of transcription factor activity or levels.  
 
 
Regulation of nucleic acid detection by TRIMs 
 
RIG-I like receptors (RLRs; including RIG-I itself, MDA-5 and Lgp2) and the AIM-2-like 
receptors (ALRs) recognise intracellular RNA and DNA, respectively. RIG-I encodes a 
DExD/H box RNA helicase that contains a caspase recruitment domain and a helicase 
domain with intact ATPase activity, both of which are responsible for dsRNA-
mediated signalling. Mitochondrial antiviral signalling protein (MAVS), is an outer-
mitochondrial membrane protein which functions downstream of RIG-I to mediate 
the activation of NFĸB/IRF3, subsequent gene activation and type I IFN production in 
response to viral infection (PMID: [64]). MAVS contains an N-terminal CARD-like 
domain and a C-terminal transmembrane domain, both of which are essential for 
MAVS signalling and subsequent interaction with TRAF3 in the case of interferon-
stimulated response element (ISRE) activation or TRAF6 in the case of NFĸB 
activation. The human HIN-200 family of proteins include AIM2 and IFI16, both of 
which act as intracellular DNA receptors (reviewed in[65]). Whilst AIM-2 regulates 
inflammasome activity and hence IL-1β maturation [66], IFI16 is critical for sensing 
DNA viruses such as HSV-1 and EBV and drives the activation of IRF3 to enhance IFN-
β production [67]. IFI16 does so via interacting with the ER-associated adaptor 
molecule STING (MITA, MYPS), promoting the relocalisation and activation of TBK1, 
resulting in IRF3 activation and IFN-β production.  
Regarding a role for TRIMs in regulating RLR and ALR activation, TRIM25 
positively regulates IFN gene induction via K63-linked ubiquitination of RIG-I. In 
doing so ubiquitinatied RIG-I can now interact with the mitochondrial associated 
adaptor MAVS and recruit the downstream kinase TBK-1 and assemble the signalling 
complex required to initiate IRF3 and NFκB activation [68]. Interestingly, activation 
of RIG-I in this context has been shown to be dependent on recognition of linear 
ubiquitin chains formed by the newly identified linear ubiquitin assembly complex 
(LUBAC) [69]. However, a recent study suggests that the LUBAC complex degrades 
TRIM25 post stimulation in order to turn off and limit RIG-I activation [70]. Perhaps 
combined these studies indicate that sequential recruitment of RIG-I and TRIM25 to 
linear ubiquitin chains may function as a mechanism to regulate RIG-I induced IFN 
production. In another twist, caspase 12 has recently been shown to positively 
regulate RIG-I mediated IFN-b in response to  West Nile virus infection, potentially 
via promoting the interaction between RIG-I and TRIM25, although the precise 
mechanism behind this is as yet unknown [71]. Given the role of IFNs in SLE, it 
remains to be seen whether TRIM25 levels or activity are altered in patients 
suffering this systemic autoimmune disease. 
With respect to DNA sensors TRIM56 has recently been shown to interact 
with and ubiquitinate STING (also known as MITA/ERIS/MYPS), an ER-associated 
adaptor protein that recruits TBK1 for dsDNA induced activation of IRF3 and 
induction of IFN [72]. The ubiquitination of STING is essential to facilitate 
dimerisation of the adaptor prior to the recruitment of TBK-1, thus marking TRIM56 
 10
as a positive facilitator of this pathway. IFI16 requires STING for its activity and is a 
well known autoantigen in systemic autoimmune disease [73]. The absolute 
requirement for STING in the production of IFN-β has come from the recent report of 
a loss-of-function variant in an American cohort that correlates with an approximate 
90% loss of IFN-β inducibility in subjects homozygous for the mutation [74].  
Interestingly, increased expression of murine HIN200 family members has been 
demonstrated to result in lupus-like syndrome in these mice, thus positively 
correlating expression of this family of proteins with autoimmunity (reviewed in [75, 
76].  Whether or not TRIM56 plays a role in regulating autoimmune progression 
remains to be determined. 
 
 
Regulation of canonical and non-canonical IKK family members 
 
Given the absolute requirement for IKK involvement in activation of either NFκB or 
IRF3/7 downstream of TLRs, RLRs or ALRs, they are an ideal point at which to 
regulate flux through these pathways. Accordingly TRIMs have been shown to either 
positively or negatively regulate responses to viruses by targeting these key proteins.   
 Probably one of the earliest reports of a TRIM family member negatively 
regulating antiviral signalling pathways demonstrated that TRIM27/Ret Finger 
Protein (RFP) could interact with both IKKα/IKKβ and IKKε /TBK1 complexes and 
inhibit transcription of NFκB- and ISRE-dependent reporter genes [27]. Although no 
known role for TRIM27 in autoimmunity is described, a weak association between 
polymorphisms in TRIM27 and Crohn’s disease, rheumatoid arthritis and type I 
diabetes has been suggested from network-based analysis of results from published 
Genome Wide Association Studies (GWAS) [77]. Recently a role for TRIM23 in 
regulating IKKs has been demonstrated. TRIM23 interacts with IKKγ/NEMO and 
catalyses its ubiquitination via K27-linked polyubiquitin chains, a modification 
critically required for IRF3 and NFκB activation downstream of TLR3 and RIG-I [78].  
Substantial evidence for cross talk between IKK family members exists, indicating the 
importance of regulatory proteins in fine tuning their activity [50]. Hence it is 
interesting to speculate that a stronger link between TRIM23 and TRIM27 in 
inflammatory and autoimmune disease may be uncovered in the future.  
 
Regulation of transcriptional responses 
 
Both GWAS studies and evidence from genetically modified mice have linked a 
number of transcription factors to the development of autoimmunity. Data is coming 
to light regarding the role for TRIMs in regulating transcription factor levels, DNA 
binding and localisation. Both TRIM19 and TRIM21 have been shown to regulate 
transcription factors directly, although the outcome of this activity (either positive or 
negative) varies greatly depending on the transcription factor involved. 
 
TRIM19/PML (promyelomonocytic leukemia protein), the principle component of 
nuclear bodies, regulates a number of transcription factors, including STAT1 and 
NFκB, albeit with opposite effects. Regarding NFκB it has been demonstrated to 
inhibit its activity by binding to the RelA/p65 subunit and physically interfering with 
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its binding to promoters [79, 80]. The involvement of PML as a positive regulator of 
IFN-γ signalling has been demonstrated to involve its RING domain, require 
SUMOylation of PML and result in enhanced phosphorylation of STAT1 [81]. In 
addition to affecting STAT1 activity, PML has also been shown to interact with PML 
Zinc Finger (PMLZF) protein and in doing so promote its binding to ISG elements and 
enhance IFN-γ mediated anti-viral gene expression [33]. Interestingly, with respect to 
a role for PML in autoimmunity, autoantigens against PML itself and other nuclear 
body proteins have been detected in patients suffering from primary biliary cirrhosis, 
an autoimmune disease of the liver, indicating that these proteins are potentially 
overexpressed in this condition or become upregulated during cellular stress [82]. 
 
A number of independent studies have demonstrated that Ro52/TRIM21 interacts 
with and regulates members of the IRF family of transcription factors, and that 
certainly, in the case of IRF3 and IRF7, promotes their ubiqutination and subsequent 
degradation in order to limit type I IFN production downstream of pathogen 
recognition. Two groups independently knocked out Ro52/TRIM21 [13, 83]. In the 
study by Espinosa et al [13], the Ro52
-/-
 mice develop a lupus-like syndrome as a 
result of activation of TLR7 and TLR9 and overproduction of type I IFNs and 
proinflammatory cytokines. However Yoshimi et al [83] failed to observe any obvious 
phenotype in their mice, although they did report impaired ubiquitination of IRF3 
and IRF8 (another substrate for Ro52/TRIM21). Different targeting strategies or 
environments have been suggested to underpin the differences in phenotypes 
observed ([84]), although perhaps the explanation lies in the manner in which both 
groups of mice were challenged – the first group investigating anti-viral responses 
and the second group challenging the mice with the bacterial TLR-4 agonist, LPS. 
Whatever the explanation, the results from Espinosa et al are intriguing, indicating 
perhaps that in addition to being a prevalent autoantigen in SLE, Ro52/TRIM21 may 
have direct effects in safeguarding against the onset of autoimmunity.   
 
Additional targets for Ro52/TRIM21 have been reported – IRF8 for example is 
positively regulated by Ro52/TRIM21 ubiquitination, resulting in modest increases in 
IL8-dependent cytokine production [85]. In a separate study Ro52/TRIM21 has been 
demonstrated to stabilise IRF3 levels and therefore positively regulates IRF3 activity 
during antiviral responses [86]. Together the data suggests that Ro52/TRIM21 
functions as a positive regulator during the initial response to a viral challenge, 
sustaining IRF3 levels, but post-viral challenge it switches (possibly through 
recruitment of additional factors) to down regulating IFN production via degradation 
of IRF3 and IRF7. Ro52 also negatively regulates NFκB activity, by targeting IKK-β for 
monoubiquitination [87]. Indeed a recent study demonstrates that Ro52 acts as a 
guardian against overactivation of IKK-β and hence NFκB, by preferentially 
recognising phosphorylated IKK-β (induced by the HTLV-1 protein TAX), and targeting 
it to autophagosomes for degradation following ubiquitination [88]. Thus the 
evidence strongly suggests that Ro52 plays an important role in preventing 
overactivation of both proinflammatory and type I IFN responses in response to viral 
infection and that if inactivated may contribute to the overproduction of cytokines 
associated with autoimmune disorders such as SLE. Given the fact that Ro52 can 
bind the Fc portion of antibodies coating internalised viruses [89], this raises the 
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intriguing possibility that immune complexes and autoantibodies against Ro52, if 
internalised may have a role in altering the function, levels or location of Ro52. 
 
 
Autoinflammatory diseases - Inflammasome regulation by TRIM family 
members 
 
The NOD-like receptors (NLR) are cytosolic sensors that mainly recognise a wide 
spectrum of danger- and pathogen-assoicated molecular patterns (DAMPs and 
PAMPs) such as ATP, DNA, RNA, flagellin and uric acid crystals and hence function in 
the regulation of inflammation and apoptotic responses. The NLR family is composed 
of 22 genes in human and 34 in mouse [90].  NLRP1, NLRP3 and NLRC4 are NLR 
family proteins involved in inflammasome assembly along with the IFI200 family 
member absent in melanoma 2 (AIM2). Assembly of the inflammasome involves one 
of either NLRP1, NLRP3, NLRC4 or AIM2 together with ASC, PYCARD and Caspase-1 
(outlined in figure 3). Once caspase-1 activation is triggered, pro-inflammatory 
cytokines IL-1β and IL-18 are processed and released [18]. Excessive inflammasome 
activation can cause autoinflammatory diseases including Type 2 Diatetes, Crohns 
Disease, Gout and Familial Mediterranean Fever [91-93]. The role of TRIMs in 
regulating inflammasome activity has been largely underappreciated. However 
emerging evidence suggests a critical role for these proteins in regulating both 
inflammasome assembly and IL-1β secretion. Interestingly two of the TRIMs involved 
in regulating inflammasome activity lack the RING domain (TRIM16 and TRIM20) 
indicating, that unless they interact with other TRIM-domain containing family 
members, ubiquitination is not required for regulation.  
 
Familial Mediterranean Fever (FMF) is an autosomal recessive disorder characterised 
by periodic recurrent bouts of fever and inflammation, representing a lack of 
regulatory control of inflammasome activity and hence IL-1β production. The gene 
responsible (MEFV) encodes TRIM20/pyrin. Some controversy surrounds the role of 
pyrin in regulating inflammasome activity, with groups reporting seemingly 
contradictory results. However, new evidence from studies of the interaction 
between pyrin and another substrate PSTPIP1 (Proline-serine-threonine 
phosphatase-interacting protein 1) provide a molecular explanation for the role of 
pyrin in regulating inflammasome activity. These studies revealed that pyrin exists as 
a homotrimer in unstimulated cells and that stimulation releases an autoinhibitory 
interaction between the N terminal SPRY domain of pyrin and its B box. This now 
frees the SPRY domain of pyrin to facilitate interaction with ASC and thus promote 
activation of the inflammasome [94].  These studies concur with the phenotype of 
mice expressing the pyrin domain alone which show enhanced IL-1β processing, 
whereas full length pyrin inhibits these responses. Thus previous in vitro studies 
reporting opposing effects of pyrin on inflammasome activation can be explained in 
light of these studies – full length pyrin by virtue of this autoinhibitory linkage with 
its B box represses inflammasome activation until the appropriate signal is received 
to cause its release (or processing) in order to drive inflammasome activity. Equally, 
processing of pyrin is similarly required in order to activate NFκB. Chae et al [16] 
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suggest that pyrin is required to be cleaved by caspase-I in order to release the pyrin 
N terminal domain which then interacts directly with the p65 subunit of NFκB thus 
promoting nuclear entry and potentiating NFκB activation. This study also linked this 
process with FMF by demonstrating that elevated levels of cleaved pyrin are 
observed in leukocytes derived from FMF patients compared with controls, 
indicating enhanced NFκB activity correlate positively with FMF.   
 
Apart from its well characterised role in FMF, additional links for pyrin with 
autoimmunity exist. For example, mutations in PSTPIP1[95], that prevent interaction 
with pyrin, have been linked to the development of PAPA syndrome (Pyogenic 
Arthritis, Pyoderma gangrenosum, Acne), an autoinflammatory condition.  [96].  In 
addition, the known mutations in pyrin (M694A and V726A) that cause FMF have 
recently been described as risk alleles for development and morbidity of multiple 
sclerosis (MS) [97]. Sepcifically these alleles are over-represented in MS cohorts and 
the frequency of MS in FMF patients is twice as high [98].   
 
TRIM16 is an estrogen responsive gene also known as estrogen-responsive B box 
protein (EBBP), initially described for its involvement in keratinocyte differentiation 
[99] and retinoid metabolism [100]. Recently a role for this protein in regulating 
secretion of the proinflammatory cytokine IL-1β has been reported [101].  TRIM16 
interacts with the inflammasome components Caspase 1 and Nalp1, and enhances 
IL-1β secretion through an alternative secretion pathway. In keeping with a role for 
TRIM16 in innate immunity and autoimmune inflammatory disease a recent study 
has demonstrated that expression of TRIM16 correlates with severity of rheumatoid 
arthritis (RA). Rheumatoid arthritis is typically characterised by pronounced 
hyperplasia of the synovium giving rise to the RA pannus. This produces 
proinflammatory cytokines and proteases that aid with the invasive properties of 
this tissue, giving rise to joint destruction and abnormalities associated with RA. A 
recent study into candidate genes that confer invasive properties to synoviocytes 
demonstrated that enhanced TRIM16 expression is closely associated with increased 
invasiveness. Whether the correlation between TRIM16 expression and enhanced 
invasiveness is as a result of altered TRIM16 regulation of IL-1β secretion remains to 
be elucidated.  
Recently TRIM16 has been shown to bind and degrade vimentin in tumours [102]. 
Vimentin is a member of the intermediate filament family of proteins and presence 
of autoantibodies that recognise a citrulinated from of vimentin are strongly 
associated with RA and are used as both a diagnostic and prognostic marker. 
Interestingly, vimentin has been reported to be released by activated macrophages 
in response to TNF-α stimulation and have bacteriacidal properties via the 
stimulation of ROS production, raising the possibility that vimentin acts as a danger 
signal or DAMP (danger associated molecular pattern) in certain environments [103]. 
One wonders therefore whether a role exists for TRIM16 in regulating either 
vimentin levels or vimentin secretion in the innate immune response, potentially 
contributing to the pathology associated with RA. 
 
TRIM30 has recently emerged as a candidate protein important in regulating IL-1β 
production in the mouse in addition to its role as a regulator of NFκB activation[104]. 
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Hu et al demonstrate that TRIM30 regulates the inflammasome by inhibiting NLRP3-
activity and hence IL-1β secretion via an unknown mechanism involving ROS 
production [17]. Interestingly, in a separate study TRIM30, along with TRIM12, have 
been identified as candidate genes for defective negative selection of autoreactive 
thymocytes during development in the NOD mice[105]. As the NOD mice display a 
defect in central tolerance this potentially indicates a global role for TRIM30 in 
regulating autoimmune disease. As the closest human orthologue to TRIM30 are 
TRIM5 and 6, it is interesting to speculate a general role for TRIM5/6 in regulating 
inflammatory cytokine production and hence autoimmune inflammatory disorders.   
 
It is well recognised that whilst normal activation of the inflammasome contributes 
to host defence, overactivation contributes to the pathogenesis of a range of 
autoinflammatory disorders, including FMF and Muckle-Wells syndrome. More 
recently the NLRP3 inflammasome was recently shown to be very important in 
regulating IL-1β production in response to IAPP in type 2 diabetic mice, again 
underlining the importance of regulating IL1-β production and the activity of NLRP3 
in preventing disease progression [106]. This raises the potential that TRIM family 
members (specifically TRIM20, 16 and 30) may be important contributors to the 
pathogenesis of these diseases. 
 
Future perspectives 
It is becoming increasingly evident that the TRIM family of E3 ligases, and specifically 
the PRY/SPRY domain containing subset, have an ever-increasing role to play in 
regulating signal transduction pathways downstream of anti-viral DNA and RNA 
sensors. Given the role of these receptors in infection, autoimmune and 
autoinflammatory disease, it is imperative that we elucidate the exact contribution 
of TRIMs to these pathways and define their precise role as potential regulators of 
autoimmune progression.  There is currently much interest in E3 ligases as 
therapeutic targets. As such, given their apparent specificity, drugs that regulate 
TRIMs should be very useful in infection and autoimmune pathology. There is 
therefore a need to understand in detail how the activity of these family members 
are regulated and whether structural motifs within their C terminal domains will be 
amenable to rationale drug design in order to control their activity.  
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Figure Legends 
 
Figure 1: TRIM structure and genomic clusters. a) Generic structure of a TRIM family 
member, including N-terminal RING-finger, B-boxes and coiled-coil domain, and 
variable C-terminal domain. Sequence homology of all TRIMs and SPRY-containing 
TRIMs are shown below using a colour spectrum with a red colour indicating high 
sequence homology. Regions in each colour spectrum represent the homology of the 
amino acids encoding the domains directly above in the general TRIM structure. 
Alignments and the subsequent homology colour spectra were produced using T-
Coffee (http://www.ebi.ac.uk/Tools/msa/tcoffee/). b) TRIM loci on chromosome 6 
and 11. While the majority of TRIMs are scattered throughout the genome, two 
TRIM clusters are located on chromosome 6p21-23 and chromosome 11p14-15. 
These TRIMs share close evolutionary relationships suggestive of recent gene 
duplications, e.g. TRIM21/Ro52 and TRIM68. Most TRIMs located at these clusters 
share a SPRY domain, known to be important for protein-ligand interactions in 
immune regulation. Phylogenetic and molecular evolutionary analyses were 
conducted using MEGA version 4 [107]. Abbreviations: ARF, ADP ribosylation factor-
like; BR, bromodomain; COS, C-terminal subgroup one signature; FN3, fibronectin 
type 3; FIL, filamin-type immunoglobulin; MATH, meprin and tumour-necrosis factor 
receptor-associated factor homology; PHD, plant homeodomain; RING, really 
interesting new gene; TRIM, tripartite-motif; TM, transmembrane. 
 
 
Supplementary Figure 1: TRIM family and domain structures. Domain structure was 
based on the SMART online domain prediction program (http://smart.embl-
heidelberg.de/). The coiled-coil domain was not detected using this program but is 
thought to be present in the majority of TRIMs.  
 
 
Figure 2: TRIM family members have been associated with the regulation of pro-
inflammatory cytokine and type I IFN production via TLR and RLR pathways.  
TRIM5α and its murine orthologue TRIM30α have been shown to negatively regulate 
NFKB promoter activity via their degradation of TAB2/3 [104].Another direct 
negative regulator of this pathway is TRIM19. TRIM19 binds p65 hence interfering 
with promoter binding [108]. Both TRIM27 and TRIM21 have been shown to interact 
with the IKKs repressing their activity and as a result pro-inflammatory cytokine 
production [27, 88]. TRIM21 also interacts with the IRFs 3, 7,8, each interaction 
resulting in repression of NFKB and IFN promoter activity [85, 109-111]. On the 
contrary, some TRIMs function as positive regulators of these pathways. TRIM25 
postively regulates IFN gene induction via its binding to the RIG-I receptor which in 
turn results in MAVS interaction [68]. TRIM56 can bind the ER-associated adaptor 
protein STING, which then recruits TBK1 for dsDNA induced activation of IRF3 and 
IFN induction [72]. TRIM23 has been demonstrated to interact with TRAF3/6 and 
NEMO downstream of TLR3/4 and RIG-I resulting in NFKB and IFN pathway activation 
[78]. TRIM20 can also positively impact NFKB promoter activity as a result of Caspase 
1 cleavage with results in pyrin domain release and interaction with the p65 subunit 
[16]. 
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Figure 3: TRIMs have been associated with the regulation of both NLRP1 and 
NLRP3 inflammasomes. Inflammasome activation results in the production of pro-
inflammatory cytokines, namely IL-1β and IL-18. TRIM16 has been shown to interact 
with both Caspase 1 and NALP1 resulting in an enhancement in IL-1β secretion [101]. 
It has been suggested that murine TRIM30α inhibits NLRP3 activity via an unknown 
mechanism involving ROS (reactive oxygen species) production [17]. Pyrin/TRIM20 
exists as a homotrimer in unstimulated cells. Inflammatory stimuli results in the 
release of an autoinhibitory interaction between pyrins N terminal SPRY domain and 
its B box domain. Once activated, the SPRY domain then interacts with ASC 
(apoptosis-associated speck-like protein containing a caspase recruitment domain) 
promoting its oligomerisation and activation of the inflammasome [94, 112]. 
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Box 1. TRIM protein structure and function 
Members of the TRIM family are easily identifiable due to the presence of the 
characteristic RING-finger, B-box and coiled coil (RBCC) domains. These N-terminal 
domains, which form the tripartite motif, are highly conserved across the TRIM 
family. The RING finger is a zinc finger motif and has been widely shown to confer E3 
ligase activity to many of the TRIM proteins
[24-26]
. The B-boxes, which are comprised 
of B-box 1 and/or 2, are zinc-binding domains, mutations in which are associated 
with diseases such as familial Mediterranean fever (and acute promyelocytic 
leukemia
B1
. The coiled coil domain is important for certain protein-protein 
interactions and can promote homo- or heterodimer formations, inducing the 
formation of complexes, such as TRIM19/PML nuclear bodies. While the preceding 
N-terminal domains are highly conserved between the TRIMs, the majority of the 
diversity in TRIM proteins is found in the C-terminal region, which consists of at least 
one of 10 unique domains and forms the basis of a TRIM classification system
B2
. The 
most prevalent C-terminal motif is the SPRY domain, which when accompanied by a 
PRY sequence is also called a B30.2 domain and is known to facilitate protein-protein 
interactions
B3
. Several TRIMs have been shown to bind target antibodies and 
proteins through the PRY/SPRY domain. Other TRIM C-terminal domains include 
COS, FN3, FIL, PHD, BR, MATH, ARF and TM (Figure 1), some of which have been 
shown to mediate both immune and non-immune functions. See Ozato et al.
[7]
 and 
Nisole et al.
[12]
 for a more detailed discussion of TRIM protein structure. 
Abbreviations: ARF, ADP ribosylation factor-like; BR, bromodomain; COS, C-terminal 
subgroup one signature; FN3, fibronectin type 3; FIL, filamin-type immunoglobulin; 
MATH, meprin and tumour-necrosis factor receptor-associated factor homology; 
PHD, plant homeodomain; PML, promyelocytic leukemia; RING, really interesting 
new gene; TRIM, tripartite-motif; TM, transmembrane. 
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Table 1: Human TRIM mRNA expression following immune cell stimulation
Stimulus TRIM Cell type Study
Induced
Type I IFN 5, 6, 14, 19, 20, 21, 22, 25, 26, 31, 34, 35, 
38, 56, 58, 69
PBL, MDM Carthagena et al.
IFNγ 19, 20, 21, 22, 25, 26, 56, 69 PBL, MDM Carthagena et al.
LPS/IFNγ 2, 3, 5, 6, 8, 10, 13, 14, 17, 18, 19, 21, 22, 
25, 26, 29, 31, 33, 34, 35, 38, 45, 46, 48, 
62, 68
Macrophage Martinez et al.
IC 9, 54 MDM Carthagena et al.
Repressed
Type I IFN 28, 37, 54, 59, 66 MDM Carthagena et al.
IFNγ 2, 4, 9, 16, 16L, 28, 32, 37, 54, 59, 66 MDM Carthagena et al.
LPS/ IFNγ 16, 23, 27, 32, 44, 52, 66 Macrophage Martinez et al.
IC 22, 32, 34, 44, 47, 58, 59, 66 MDM Carthagena et al.
Abbreviations: IC, immune complex; IFN, interferon; LPS, lipopolysaccharide; MDM, monocyte-derived 
macrophage; PBL, peripheral blood lymphocyte.
Table 2: Human TRIMs and the viral life-cycle
Effect of TRIM HIV N-MLV B-MLV ALV Reference
Viral entry
Enhance 8 11 - ND
Decrease 5, 11, 26, 
31
1, 5, 25, 26, 62 25, 26, 62 ND Sebastian et al 
2005
Viral gene expression
Enhance - - ND -
Decrease 5, 11, 22 1, 11, 13, 14, 
21, 27, 31, 32, 
62
ND - Sakuma et al 2007, 
Tareen et al 2009,  
Singh et al 2011
Viral release
Enhance - - ND -
Decrease 11, 15, 22,
26, 32
1, 5, 8, 11, 13, 
14, 15, 19, 21, 
25, 26, 27, 28, 
31, 32, 35, 62
ND 25, 32 Barr et al 2008
Data from Uchil et al 2008. Target cells HEK293. Abbreviations: ALV, avian leukosis virus; HIV, human 
immunodeficiency virus 1; B-MLV B-tropic murine leukemia virus; ND, not determined; N-MLV, N-tropic murine 
leukemia virus; TRIM, tripartite motif. Highlighted TRIMs have been confirmed at these stages based on this review.
